Quick Answer
Anbio Biotechnology reported Total Revenue of $8.19 million for fiscal year 2024.
Anbio Biotechnology — Key Financials by Year
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Total Revenue | $8.19M +21.9% |
$6.71M -71.5% |
$23.54M |
| Net Income | $2.37M +5.3% |
$2.25M -77.5% |
$10.01M |
| Diluted EPS | $0.06 -46.7% |
$0.10 -100.0% |
$100112.00 |
| Total Assets | $18.92M +19.7% |
$15.81M | — |
| Cash and Equivalents | $11.76M +21.4% |
$9.69M | — |
| Stockholders Equity | $17.19M +16.0% |
$14.82M +18.1% |
$12.55M |
| R&D Expense | $454.2K +237.2% |
$134.7K -32.6% |
$200.0K |
| Operating Income | $2.00M +1.8% |
$1.96M -80.8% |
$10.20M |
| Gross Profit | $5.89M +75.1% |
$3.36M -73.2% |
$12.56M |
- Anbio Biotechnology reported Total Revenue of $8.19 million for fiscal year 2024.
- Anbio Biotechnology showed an increase of +21.9% in Total Revenue compared to the prior fiscal year.
- Anbio Biotechnology reported Net Income of $2.37 million for fiscal year 2024.
- Anbio Biotechnology showed an increase of +5.3% in Net Income compared to the prior fiscal year.
- Anbio Biotechnology reported Diluted EPS of $0.06 per share for fiscal year 2024.
- Anbio Biotechnology showed a decrease of -46.7% in Diluted EPS compared to the prior fiscal year.
- Anbio Biotechnology reported Total Assets of $18.92 million for fiscal year 2024.
- Anbio Biotechnology showed an increase of +19.7% in Total Assets compared to the prior fiscal year.
- Anbio Biotechnology reported Cash and Equivalents of $11.76 million for fiscal year 2024.
- Anbio Biotechnology showed an increase of +21.4% in Cash and Equivalents compared to the prior fiscal year.
- Anbio Biotechnology reported Stockholders Equity of $17.19 million for fiscal year 2024.
- Anbio Biotechnology showed an increase of +16.0% in Stockholders Equity compared to the prior fiscal year.
- Anbio Biotechnology reported R&D Expense of $454.2 thousand for fiscal year 2024.
- Anbio Biotechnology showed an increase of +237.2% in R&D Expense compared to the prior fiscal year.
- Anbio Biotechnology reported Operating Income of $2.00 million for fiscal year 2024.
- Anbio Biotechnology showed an increase of +1.8% in Operating Income compared to the prior fiscal year.
- Anbio Biotechnology reported Gross Profit of $5.89 million for fiscal year 2024.
- Anbio Biotechnology showed an increase of +75.1% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: